Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes - Gan, Li-Ming; Lagerström-Fermér, Maria; Carlsson, Leif G.; Arfvidsson, Cecilia; Egnell, Ann-Charlotte; Rudvik, Anna; Kjaer, Magnus; Collén, Anna; Thompson, James D.; Joyal, John; Chialda, Ligia; Koernicke, Thomas; et al. (Nature communications, 2019)
Keywords: 42/109; 42/44; 59; 631/443/319/1642/137/138; 631/443/592/16; 631/61/391; Adult; Aged; Angiogenesis; Biocompatibility; Blood flow; Cardiology and Cardiovascular Disease; cardiovascular gene-therapy; Clinical trials; Coding; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - therapy; Doppler effect; endothelial growth-factor; foot; Forearm; Gene expression; Genetic Therapy; Growth factors; Humanities and Social Sciences; Humans; infarction; injection; Injections, Intradermal; Kardiologi och kardiovaskulära sjukdomar; Male; Microdialysis; Middle Aged; mRNA; multidisciplinary; Neovascularization, Physiologic - physiology; Organic chemistry; Placebos - administration & dosage; Protein expression; Proteins; Regional Blood Flow - genetics; RNA, Messenger - adverse effects; RNA, Messenger - genetics; RNA, Messenger - therapeutic use; Science; Science & Technology - Other Topics; Science (multidisciplinary); Skin; Skin - blood supply; vaccines; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - genetics